Together, these results indicate that MYC targeting confers vulnerability of HCC cells to cabozantinib, converting a partial cytostatic (triggered by single treatment) into a cytotoxic effect (achieved by combined treatment). This evidence concerns the gene MYC and hepatocellular carcinoma.